Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
OptiBiotix Health inks manufacturing deal with KAG Industries
(Sharecast News) - Life sciences company OptiBiotix Health announced on Tuesday that its its Indian subsidiary, OptiBiotix Health India (OHI), has entered into a manufacturing agreement with KAG Industries for the supply of 'Slimbiome' products tailored for the Indian market. The AIM-traded firm said KAG, a specialised contract manufacturer of nutritional powders with its own research and development facilities, had crafted five unique flavours specifically designed for the Indian consumer.
It said the products would be marketed by OHI to Dr Morepen, a well-established brand in India dedicated to promoting customer health and well-being since 2001.
OptiBiotix said India represented a strategic market, with its population of 1.4 billion and a notable obesity prevalence of 40.3%.
The burgeoning middle-class population, expected to reach 475 million by 2030, presented a significant growth opportunity.
OptiBiotix said it was aiming to capitalise on that trend, particularly as India emerged as a dominant hub for global middle-class consumers by 2035.
"We are pleased to announce this agreement with KAG to support the launch of SlimBiome containing products with Dr Morepen, a well-known and trusted supplier to pharmacies, physicians, and retail customers across India," said chief executive officer Stephen O'Hara.
"We look forward to the upcoming launch of products across India with Dr Morepen and our manufacturing partners."
At 1630 BST, shares in OptiBiotix Health were up 5.8% at 18.25p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
